Sangamo Therapeutics, Inc.
Narrative signal
Sangamo Therapeutics, Inc.’s revenue growth stands at -67.2% for Dec 2024. Year-over-year, the metric shifted by −125.5 pts, translating into a −215.19% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Sangamo Therapeutics, Inc. trades at $0.4959 with a market footprint around $166.9M.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at -67.2%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Sangamo Therapeutics, Inc. (SGMO) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Sangamo Therapeutics, Inc. (SGMO) stock price today?
Sangamo Therapeutics, Inc. (SGMO) trades near $0.4959 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Sangamo Therapeutics, Inc.'s market capitalization?
Sangamo Therapeutics, Inc.'s equity is valued around $166.9M, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Sangamo Therapeutics, Inc.?
Sangamo Therapeutics, Inc.'s 52-week range runs from $0.38 — $2.84. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Sangamo Therapeutics, Inc. stock?
Sangamo Therapeutics, Inc. most recently moved about 4.9M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Sangamo Therapeutics, Inc. pay a dividend?
Sangamo Therapeutics, Inc. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Sangamo Therapeutics, Inc.'s intraday trading range?
Sangamo Therapeutics, Inc. has traded between $0.4912 — $0.528 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Sangamo Therapeutics, Inc. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Sangamo Therapeutics, Inc. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.